List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 111 studies with search of:   "Vorinostat"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Not yet recruiting Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
Condition: Malignant Solid Tumour
Intervention: Drug: Zolinza (vorinostat), vinorelbine
2 Not yet recruiting SAHA +CHOP in Untreated T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat);   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
3 Recruiting Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Conditions: Glioblastoma Multiforme;   Anaplastic Glioma
Interventions: Drug: Vorinostat;   Drug: Carboplatin;   Drug: Isotretinoin;   Other: No Surgery;   Procedure: Surgical Resection
4 Not yet recruiting Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Vorinostat;   Drug: Bortezomib
5 Terminated Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
Condition: Non-Small Cell Lung, Prostate, Bladder/Urothelial Cancers.
Interventions: Drug: vorinostat (suberoylanilide hydroxamic acid);   Drug: docetaxel
6 Recruiting A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Paclitaxel, Carboplatin and Vorinostat
7 Recruiting Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML
Conditions: Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS)
Interventions: Drug: Idarubicin;   Drug: Cytarabine;   Drug: Vorinostat
8 Recruiting Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Interventions: Drug: Vorinostat, Carboplatin, Etoposide;   Other: Vorinostat, Carboplatin, Etoposide
9 Recruiting Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel;   Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
10 Recruiting HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Condition: Advanced Breast Cancer
Intervention: Drug: Vorinostat
11 Active, not recruiting A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer
Conditions: Advanced Cancer Relapsed;   Advanced Cancer Refractory
Interventions: Drug: vorinostat;   Drug: Comparator: placebo (unspecified)
12 Not yet recruiting Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Conditions: Hematologic Malignancies;   Graft vs Host Disease
Interventions: Procedure: reduced intensity, matched related donor stem cell transplant;   Drug: tacrolimus (standard GVHD prophylaxis);   Drug: mycophenolate (standard GVHD prophylaxis);   Drug: vorinostat
13 Recruiting Vorinostat (MK0683, SAHA) + Revlimid + Dexamethasone in Multiple Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: vorinostat;   Drug: Comparator: lenalidomide;   Drug: Comparator: Dexamethasone
14 Active, not recruiting Phase IIa Vorinostat (MK 0683, SAHA) Study in Lower Risk Myelodysplastic Syndromes
Conditions: Myelodysplastic Syndromes;   Blood Disease;   Bone Marrow Disease
Intervention: Drug: vorinostat
15 Recruiting Compassionate Use of Vorinostat (MK0683, SAHA) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
Condition: Lymphoma, T-Cell, Cutaneous
Intervention: Drug: vorinostat
16 Active, not recruiting Study of Vorinostat (MK0683, SAHA) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Suberoylanilide Hydroxamic Acid (SAHA);   Drug: Bortezomib
17 Active, not recruiting A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma
Condition: Malignant Lymphoma
Intervention: Drug: vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)
18 Active, not recruiting A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Solid Tumors
Condition: Tumors
Intervention: Drug: vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)
19 Terminated A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions: Stage IIIB or IV Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Comparator: vorinostat;   Drug: Comparator: paclitaxel;   Drug: Comparator: carboplatin;   Drug: Comparator: placebo
20 Not yet recruiting A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Vorinostat

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services